arrow
M

Marcela Valverde-Monge

fundacion jimenez diaz university hospital
H指数:14
被引数:898

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Differential Effects of Benralizumab and Mepolizumab on Pro-Resolving Mediators

苯那利珠单抗和美泊利珠单抗对促消退介质的差异性影响

2026-04-170
OAAI
FEV1Q as a Predictive Metric for Asthma Outcomes

FEV1Q作为预测哮喘结局的指标

2025-03-010
PRE
Single-cell RNA sequencing of human blood eosinophils reveals plasticity and absence of canonical cell subsets
2024-06-272
OAAI
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

在严重哮喘患者的现实队列中,使用不同标准比较奥马珠单抗和Anti-IL-5/IL-5R的长期反应和缓解

2024-01-014
OA
Reply to Olfactory Function and Biologic Treatments: A Comment on Available Real-life Studies

对嗅觉功能和生物治疗的回复: 对现有现实生活研究的评论

2023-12-130
OA
Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

西班牙哮喘队列中与工作相关的哮喘的处置: 在职和退休工人之间哮喘严重程度的比较

2023-11-014
OAAI
The New ERS/ATS 2022 Bronchodilator Response Recommendation: Comparison With the Previous Version in an Asthma Cohort

新的ERS/ATS 2022支气管扩张剂反应建议: 在哮喘队列中与以前版本的比较

2023-09-014
OAAI
Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma
2023-07-272
OA
Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

哮喘患者的急性加重在很大程度上取决于共病的存在。

2023-07-276
OA
EAACI Molecular Allergology User's Guide 2.0

EAACI分子变态反应学用户指南2.0

2023-04-26153
OA